ICLR Company Profile and Key Details

Q: Who are the executives of ICLR?

Mr. Brendan BrennanChief Financial OfficerMr. Simon HolmesPres of Corporation Investments & PartnershipsMs. Niamh MurphyDirector of Corporation CommunicationsJonathan CurtainSenior Vice President of Corporation & Commercial Fin.Mr. Diarmaid CunninghamChief Admin. Officer, Gen. Counsel & Company Sec.Ms. Dana Lynn Poff Snr.Executive Vice President of Program ManagementDr. Steven A. Cutler MBA, Ph.D.Chief Executive Officer & DirectorDr. Gary CurtisSenior Vice President of Global Clinical PharmacologyMr. Joe CroninChief HR OfficerMr. Thomas N. O'LearyChief Information Officer

NASDAQ : ICLR

ICON Public

$177.09

3.375+1.94%

Open: 3:10 PM

64.78

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

ICON Public Limited Company (ICLR) stock surged +1.94%, trading at $177.09 on NASDAQ, up from the previous close of $173.71. The stock opened at $174.00, fluctuating between $173.22 and $181.82 in the recent session.

Stock Snapshot

173.71

Prev. Close

13.56B

Market Cap

173.22

Day Low

14.44

P/E Ratio

12.26

EPS (TTM)

12.27

Cash Flow per Share

174

Open

76.57M

Number of Shares

181.815

Day High

98.74%

Free Float in %

112.15

Book Value

569.54K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 30, 2026	178.29	181.00	170.85	173.71	1.07M
Jun 29, 2026	169.65	173.51	167.24	172.99	1.36M
Jun 26, 2026	158.59	170.51	158.59	169.86	1.44M
Jun 25, 2026	161.92	168.63	160.47	160.96	2.25M
Jun 24, 2026	147.79	162.00	147.71	158.17	2.41M
Jun 23, 2026	139.72	145.01	138.84	142.67	691.4K
Jun 22, 2026	145.77	148.00	140.14	140.73	918.71K
Jun 18, 2026	145.32	146.51	141.70	146.00	870.05K
Jun 17, 2026	143.65	145.09	140.00	143.27	989.82K
Jun 16, 2026	148.88	148.88	142.93	143.54	568.5K
Jun 15, 2026	147.20	148.74	144.84	147.72	598.03K
Jun 12, 2026	150.11	151.53	143.86	146.18	703.87K
Jun 11, 2026	144.89	149.97	143.30	149.92	790.29K
Jun 10, 2026	152.15	154.27	144.31	144.59	1.01M
Jun 09, 2026	152.93	156.20	150.32	151.82	1.22M
Jun 08, 2026	149.45	153.94	147.17	152.24	1.13M
Jun 05, 2026	151.78	153.75	147.97	149.45	1.35M
Jun 04, 2026	144.28	153.84	144.28	152.80	1.69M
Jun 03, 2026	136.79	145.92	135.52	143.90	1.36M
Jun 01, 2026	133.70	138.46	132.36	138.03	1.31M

Contact Details

Dublin, D18 X5R3

Ireland

https://www.iconplc.com 353 129 12000

About Company

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Stock Peers

MEDP

-5.13-0.96%

Medpace Holdings, Inc.$529.59 IDXX

-9.49-1.77%

IDEXX Laboratories, Inc.$526.44 NTRA

-0.86-0.32%

Natera, Inc.$271.45 ILMN

-5.27-2.91%

Illumina, Inc.$175.83 GH

-3.71-2.41%

Guardant Health, Inc.$150.03 BLLN

-0.42-0.35%

BillionToOne, Inc.$119.98 ILMNV

1.75+1.66%

Illumina, Inc. Common Stock Ex-distribution When-Issued$107.00 EXAS

Exact Sciences Corporation$104.91 TWST

4.52+4.60%

Twist Bioscience Corporation$102.88 RDNT

2.39+4.03%

RadNet, Inc.$61.67

Company Overview

ICON Public Limited Company (NASDAQ:ICLR) closed at $177.09 USD, gaining $3.38 (1.94%) from the previous close of $173.71. The stock is currently mid-range between its 52-week high and low $66.57 and $211.00. With a market capitalization of about $13.56 billion, ICON Public Limited Company is classified as a large-cap and shows market-like volatility (beta ~1.27). Key stats such as the average daily volume over the past year has been around 1.21 million shares, volume is running light vs its 52-week average. Headquartered in Dublin, None, ICON Public Limited Company operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Barry Balfe, the company employs approximately 40,950 people and listed since May 15, 1998. ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.

Technical Performance

ICLR has shown mixed momentum, losing -1.99% over the past week and -4.59% over the past quarter, though year-to-date performance is down -3.1%. Short-term trend indicators are bullishly aligned (SMA20 -17.61%, SMA50 -34.66%, SMA200 -35.2%). The stock’s 14-day RSI is 34.59 (weak momentum), while the ATR of 9.95 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -49.7% below its high and over 59.43% above its low. Average 10-day trading volume of 1.45 million shares is slightly above the 3-month average of 1.19 million, indicating heightened recent market interest.

Valuation Metrics

ICON Public Limited Company trades at a P/E ratio of 30.72, slightly below the S&P 500 average, with a price-to-sales ratio of 1.62 and a price-to-book ratio of 1.43 suggesting the stock is closer to book value. The P/FCF stands at 10.75, also above market averages.

Dividend & Fair Value

ICON Public Limited Company last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $161.36. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

ICON Public Limited Company generated EPS of $7.40 over the past year. Five-year average earnings growth is 6.54%. Wall Street analysts project EPS growth of -1.09% annually over the next five years. The latest quarter delivered EPS of $2.50. The next quarter is forecast at $3.23. Next year's EPS is expected at $16.56. Analyst sentiment is neutral. Analyst rating data shows there are 12 Strong Buy ratings, 8 Buy ratings, 23 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $240.00 to $120.00. The high target offers 38.16% upside. The low target suggests -30.92% downside. The mean target is $180.13. This offers 3.7% upside. ICON Public Limited Company earnings surprise history is a mixed track record. The quarter that ended June 23, 2026, missed forecasts by 2.88%. The prior quarter beat by 2.02%. Over the last six quarters, Apple has recorded several small beats. These include 0.91% in October 22, 2025.

Shareholding & Insider Activity

ICON Public Limited Company has 77.77 million shares outstanding. The public float is 76.80 million shares, elevated short interest at 2.71% of float. This equals 2.09 million shares. The short ratio is 1.26 days. Institutional investors hold 103.4% of the float. Insiders own 0.65%.

Financial & Profitability Overview

Over the trailing twelve months, ICON Public generated $8.12B in revenue, or $98.17 per share. Gross margin was 22.34%, operating margin 13.04%, and net profit margin 7.54%. Returns are modest, with ROA at 3.60% and ROE at 6.63%.
On valuation metrics, ICON Public trades at a P/E of 30.72, P/S of 1.62 and P/B of 1.43. The current ratio is 1.14 and quick ratio is 1.14. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 114.15 days. Debt-to-equity is 0.38, supported by a cash flow-to-debt ratio of 0.43.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, ICON Public posted revenue of $8.12B, down slightly from $7.74B in the prior quarter. Gross profit was $1.81B (margin 22.34%). Operating income was $1.06B (margin 13.0%). Net income was$612.34M (EPS $7.46).
The company ended the quarter with $380.06M in cash and short-term investments, a total debt of $3.94B, and net debt of $3.56B. Total assets were $16.99B, with equity of $9.24B. Financials further reflected stability, with operating cash flow of $1.16B, free cash flow of $1.02B, and capital expenditures of - $140.69M.

Price Forecast & Outlook

Our AI price prediction model suggests that ICON Public Limited Company stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.84%, with price expected at $185.59 by July 14, 2026, within a range of $175.69 to $195.19 3-Month Outlook: Projected rise of 38.0%, reaching $239.72 by September 28, 2026, with a range of $217.27 to $261.24. 1-Year Outlook: Projected loss of -36.21%, with price at $110.81 by June 30, 2027, within a range of $91.14 to $127.10.

Key Takeaways

ICON Public Limited Company (NASDAQ:ICLR) shares are flat -3.1% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ICON Public Limited Company trading at a premium to the broader market with a P/E of 30.72. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $235.28, suggesting 35.44% upside. Our AI forecast model points to short-term strength (6.84% over two weeks), a medium-term rise (38.0% over three months), and a longer-term loss (-36.21% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current ICON Public Limited Company (ICLR) stock price?

ICON Public Limited Company (NASDAQ: ICLR) stock price is $177.09 in the last trading session. During the trading session, ICLR stock reached the peak price of $181.82 while $173.22 was the lowest point it dropped to. The percentage change in ICLR stock occurred in the recent session was 1.94% while the dollar amount for the price change in ICLR stock was $3.38.

ICLR's industry and sector of operation?

The NASDAQ listed ICLR is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. ICON Public Limited Company designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ICLR?

Mr. Brendan Brennan
Chief Financial Officer
Mr. Simon Holmes
Pres of Corporation Investments & Partnerships
Ms. Niamh Murphy
Director of Corporation Communications
Jonathan Curtain
Senior Vice President of Corporation & Commercial Fin.
Mr. Diarmaid Cunningham
Chief Admin. Officer, Gen. Counsel & Company Sec.
Ms. Dana Lynn Poff Snr.
Executive Vice President of Program Management
Dr. Steven A. Cutler MBA, Ph.D.
Chief Executive Officer & Director
Dr. Gary Curtis
Senior Vice President of Global Clinical Pharmacology
Mr. Joe Cronin
Chief HR Officer
Mr. Thomas N. O'Leary
Chief Information Officer

How ICLR did perform over past 52-week?

ICLR's closing price is 160.94% higher than its 52-week low of $66.57 where as its distance from 52-week high of $211.00 is -17.67%.

How many employees does ICLR have?

Number of ICLR employees currently stands at 40,950.

Link for ICLR official website?

Official Website of ICLR is: https://www.iconplc.com

How do I contact ICLR?

ICLR could be contacted at phone 353 129 12000 and can also be accessed through its website. ICLR operates from South County Business Park, Dublin, D18 X5R3, Ireland.

How many shares of ICLR are traded daily?

ICLR stock volume for the day was 569.54K shares. The average number of ICLR shares traded daily for last 3 months was 1.21M.

What is the market cap of ICLR currently?

The market value of ICLR currently stands at $13.56B with its latest stock price at $177.09 and 76.57M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	40950
Beta	1.27
Sales or Revenue	$8.12B
5Y Sales Change%	1.062%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

ICLR Company Profile and Key Details

ICON Public

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics